Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment

Detalhes bibliográficos
Autor(a) principal: Coimbra, Judite R. M.
Data de Publicação: 2018
Outros Autores: Marques, Daniela F. F., Baptista, Salete J., Pereira, Cláudia Fragão, Moreira, Paula I., Dinis, Teresa C. P., Santos, Armanda E., Salvador, Jorge A. R.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10316/107605
https://doi.org/10.3389/fchem.2018.00178
Resumo: Alzheimer's disease (AD) is a severe neurodegenerative disorder and the most common type of dementia in the elderly. The clinical symptoms of AD include a progressive loss of memory and impairment of cognitive functions interfering with daily life activities. The main neuropathological features consist in extracellular amyloid-β (Aβ) plaque deposition and intracellular Neurofibrillary tangles (NFTs) of hyperphosphorylated Tau. Understanding the pathophysiological mechanisms that underlie neurodegeneration in AD is essential for rational design of neuroprotective agents able to prevent disease progression. According to the "Amyloid Cascade Hypothesis" the critical molecular event in the pathogenesis of AD is the accumulation of Aβ neurotoxic oligomers. Since the proteolytic processing of Amyloid Precursor Protein (APP) by β-secretase (beta-site APP cleaving enzyme 1, BACE1) is the rate-limiting step in the production of Aβ, this enzyme is considered a major therapeutic target and BACE1 inhibitors have the potential to be disease-modifying drugs for AD treatment. Therefore, intensive efforts to discover and develop inhibitors that can reach the brain and effectively inhibit BACE1 have been pursued by several groups worldwide. The aim of this review is to highlight the progress in the discovery of potent and selective small molecule BACE1 inhibitors over the past decade.
id RCAP_5cc7d72ece47d73e3ad75ee6a4e3eef5
oai_identifier_str oai:estudogeral.uc.pt:10316/107605
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Highlights in BACE1 Inhibitors for Alzheimer's Disease TreatmentAlzheimer’s Disease (AD)Amyloid-β (Aβ)BACE1inhibitorssmall moleculesdrug discovery and developmentAlzheimer's disease (AD) is a severe neurodegenerative disorder and the most common type of dementia in the elderly. The clinical symptoms of AD include a progressive loss of memory and impairment of cognitive functions interfering with daily life activities. The main neuropathological features consist in extracellular amyloid-β (Aβ) plaque deposition and intracellular Neurofibrillary tangles (NFTs) of hyperphosphorylated Tau. Understanding the pathophysiological mechanisms that underlie neurodegeneration in AD is essential for rational design of neuroprotective agents able to prevent disease progression. According to the "Amyloid Cascade Hypothesis" the critical molecular event in the pathogenesis of AD is the accumulation of Aβ neurotoxic oligomers. Since the proteolytic processing of Amyloid Precursor Protein (APP) by β-secretase (beta-site APP cleaving enzyme 1, BACE1) is the rate-limiting step in the production of Aβ, this enzyme is considered a major therapeutic target and BACE1 inhibitors have the potential to be disease-modifying drugs for AD treatment. Therefore, intensive efforts to discover and develop inhibitors that can reach the brain and effectively inhibit BACE1 have been pursued by several groups worldwide. The aim of this review is to highlight the progress in the discovery of potent and selective small molecule BACE1 inhibitors over the past decade.Frontiers Media S.A.2018info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://hdl.handle.net/10316/107605http://hdl.handle.net/10316/107605https://doi.org/10.3389/fchem.2018.00178eng2296-2646Coimbra, Judite R. M.Marques, Daniela F. F.Baptista, Salete J.Pereira, Cláudia FragãoMoreira, Paula I.Dinis, Teresa C. P.Santos, Armanda E.Salvador, Jorge A. R.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-24T08:35:29Zoai:estudogeral.uc.pt:10316/107605Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:23:56.375013Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment
title Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment
spellingShingle Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment
Coimbra, Judite R. M.
Alzheimer’s Disease (AD)
Amyloid-β (Aβ)
BACE1
inhibitors
small molecules
drug discovery and development
title_short Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment
title_full Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment
title_fullStr Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment
title_full_unstemmed Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment
title_sort Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment
author Coimbra, Judite R. M.
author_facet Coimbra, Judite R. M.
Marques, Daniela F. F.
Baptista, Salete J.
Pereira, Cláudia Fragão
Moreira, Paula I.
Dinis, Teresa C. P.
Santos, Armanda E.
Salvador, Jorge A. R.
author_role author
author2 Marques, Daniela F. F.
Baptista, Salete J.
Pereira, Cláudia Fragão
Moreira, Paula I.
Dinis, Teresa C. P.
Santos, Armanda E.
Salvador, Jorge A. R.
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Coimbra, Judite R. M.
Marques, Daniela F. F.
Baptista, Salete J.
Pereira, Cláudia Fragão
Moreira, Paula I.
Dinis, Teresa C. P.
Santos, Armanda E.
Salvador, Jorge A. R.
dc.subject.por.fl_str_mv Alzheimer’s Disease (AD)
Amyloid-β (Aβ)
BACE1
inhibitors
small molecules
drug discovery and development
topic Alzheimer’s Disease (AD)
Amyloid-β (Aβ)
BACE1
inhibitors
small molecules
drug discovery and development
description Alzheimer's disease (AD) is a severe neurodegenerative disorder and the most common type of dementia in the elderly. The clinical symptoms of AD include a progressive loss of memory and impairment of cognitive functions interfering with daily life activities. The main neuropathological features consist in extracellular amyloid-β (Aβ) plaque deposition and intracellular Neurofibrillary tangles (NFTs) of hyperphosphorylated Tau. Understanding the pathophysiological mechanisms that underlie neurodegeneration in AD is essential for rational design of neuroprotective agents able to prevent disease progression. According to the "Amyloid Cascade Hypothesis" the critical molecular event in the pathogenesis of AD is the accumulation of Aβ neurotoxic oligomers. Since the proteolytic processing of Amyloid Precursor Protein (APP) by β-secretase (beta-site APP cleaving enzyme 1, BACE1) is the rate-limiting step in the production of Aβ, this enzyme is considered a major therapeutic target and BACE1 inhibitors have the potential to be disease-modifying drugs for AD treatment. Therefore, intensive efforts to discover and develop inhibitors that can reach the brain and effectively inhibit BACE1 have been pursued by several groups worldwide. The aim of this review is to highlight the progress in the discovery of potent and selective small molecule BACE1 inhibitors over the past decade.
publishDate 2018
dc.date.none.fl_str_mv 2018
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10316/107605
http://hdl.handle.net/10316/107605
https://doi.org/10.3389/fchem.2018.00178
url http://hdl.handle.net/10316/107605
https://doi.org/10.3389/fchem.2018.00178
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2296-2646
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Frontiers Media S.A.
publisher.none.fl_str_mv Frontiers Media S.A.
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134125222789120